SciSparc Ltd. stock analysis
SciSparc Ltd. (SPRC) Stock Price & Analysis
SPRC Stock Chart & Stats
- Day’s Range
- $0.27 - $0.39
- 52-Week Range
- $0.23 - $29.87
- Previous Close
- $0.27
- Volume
- N/A
- Average Volume (3M)
- 5.83M
- Market Cap
- $617.32K
- Enterprise Value
- -$3.76T
- Total Cash (Recent Filing)
- $4.44M
- Total Debt (Recent Filing)
- $2.68M
- Price to Earnings (P/E)
- ―
- Beta
- 1.99
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
SciSparc Ltd. News
SciSparc Shifts Focus to Agentic AI, Targeting Cybersecurity and Finance Applications
TEL AVIV, Israel, October 26th, 2026, FinanceWire SciSparc Ltd. (Nasdaq:SPRC) (“Company” or “SciSparc”), announced that it will shift its strategic focus toward Agentic AI-powered technologies, including cybersecurity and finance technologies.
SPRC FAQ
What was SciSparc Ltd.’s price range in the past 12 months?
What is SciSparc Ltd.’s market cap?
When is SciSparc Ltd.’s upcoming earnings report date?
How were SciSparc Ltd.’s earnings last quarter?
Is SciSparc Ltd. overvalued?
Does SciSparc Ltd. pay dividends?
What is SciSparc Ltd.’s EPS estimate?
How many shares outstanding does SciSparc Ltd. have?
What happened to SciSparc Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of SciSparc Ltd.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
SciSparc Ltd.
SciSparc Ltd. is a pharmaceutical company in the clinical development phase, specializing in creating medications derived from cannabinoid molecules. Their therapeutic pipeline encompasses several key drug candidates: SCI-110, which is being investigated for the treatment of Tourette syndrome, obstructive sleep apnea, and agitation associated with Alzheimer's disease; SCI-160, designed to address pain; and SCI-210, targeting autism spectrum disorder and epilepsy. The company has formed strategic alliances to further its goals. A partnership with Procaps focuses on the development and eventual commercial manufacturing of SCI-110, as well as CannAmide, an oral palmitoylethanolamide in a soft gel capsule. SciSparc is also collaborating with the Sheba Fund for Health Services and Research to explore SCI-210's potential in managing status epilepticus. Additionally, it has teamed up with The Israeli Medical Center for Alzheimer's to conduct a Phase IIa clinical trial, evaluating the safety, tolerability, and effectiveness of SCI-110 for patients experiencing Alzheimer's disease and agitation. Founded in 2004, the company initially operated under the name Therapix Biosciences Ltd. before changing to SciSparc Ltd. in January 2021. Its main corporate office is located in Tel Aviv-Yafo, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Oz Adler
- Employees
- 3
- Website
- scisparc.com
- Address
- Tower A, Tel Aviv, TA, 6971916, IL
SciSparc Ltd. (SPRC) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 3 | 15 |
| Technical Analysis | 4 | 3 | 3 |
| Moving Averages | 0 | 0 | 12 |










